<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39318867</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2645-4904</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Archives of academic emergency medicine</Title><ISOAbbreviation>Arch Acad Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Feasibility and Effectiveness of Vaccines for COVID-19: An Umbrella Review.</ArticleTitle><Pagination><StartPage>e6</StartPage><MedlinePgn>e6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.22037/aaem.v12i1.2357</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">In January 2020, WHO declared the 2019 Coronavirus Disease (COVID-19) a pandemic. Though COVID-19 vaccines are recommended, ongoing surveillance is crucial due to potential unforeseen events. Evaluation of long-term effectiveness and safety and addressing emerging variants are vital. This study integrates systematic reviews to assess COVID-19 vaccine efficacy, immunogenicity, and safety comprehensively.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study was an umbrella review study on the feasibility and effectiveness of vaccines for COVID-19. We conducted a comprehensive search in PubMed, Web of Sciences, and Scopus, using MeSH terms and keywords related to COVID-19 vaccines. Inclusion criteria comprised peer-reviewed systematic reviews and meta-analyses in English, focusing on feasibility and effectiveness. Exclusion criteria targeted non-systematic reviews exclusively on vaccine safety and duplicates. Two independent reviewers screened and resolved discrepancies. Data extraction included key details. Methodological quality was assessed using the ROBIS tool. Data synthesis involves narrative and, if applicable, quantitative synthesis (meta-analysis). Reporting followed PRISMA guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 32 systematic reviews were included in the study, of which 20 also conducted a meta-analysis. The studies investigated in the included reviews ranged from 7 to 74. The included articles were conducted in various countries around the globe. The findings indicated that COVID-19 vaccines are generally safe and effective for individuals with various medical conditions. The overall risk of bias for the included studies was assessed as low risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The study outcomes indicated that mRNA vaccines exhibit a higher incidence of adverse events but demonstrate greater efficacy. Conversely, inactivated and protein subunit vaccines are safer but exhibit lower efficiency. Moreover, the vaccine is considered safe for individuals with specific conditions such as inflammatory bowel disease, solid organ transplant recipients, children, pregnant individuals, and those with hematologic problems. Ultimately, the acceptance of the COVID-19 vaccine among individuals is influenced by various factors, including geographic, socioeconomic, and pandemic-related considerations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>SeyedAlinaghi</LastName><ForeName>SeyedAhmad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pashapouryeganeh</LastName><ForeName>Amirreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cofirst author.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehghani</LastName><ForeName>Soheil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Prevention ofMetabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzapour</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbaspour</LastName><ForeName>Faeze</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School ofMedicine, Tehran University ofMedical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afroughi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimzadeh</LastName><ForeName>Payman</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Surgical Research Society (SRS), Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najafi</LastName><ForeName>Morvarid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School ofMedicine, Tehran University ofMedical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Hoomaan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School ofMedicine, Tehran University ofMedical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozafari</LastName><ForeName>Navid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School ofMedicine, Bushehr University of Medical Sciences, Bushehr, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltanali</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Medical student in Ilam University of Medical Sciences, Ilam, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehraeen</LastName><ForeName>Esmaeil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Arch Acad Emerg Med</MedlineTA><NlmUniqueID>101740147</NlmUniqueID><ISSNLinking>2645-4904</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Effectiveness</Keyword><Keyword MajorTopicYN="N">Feasibility</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest regarding the publication of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39318867</ArticleId><ArticleId IdType="pmc">PMC11417638</ArticleId><ArticleId IdType="doi">10.22037/aaem.v12i1.2357</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehraeen E, Dadras O, Afsahi AM, Karimi A, Pour MM, Mirzapour P, et al. Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infectious disorders drug targets. 2022;22(2):e230921196758.</Citation><ArticleIdList><ArticleId IdType="pubmed">34554905</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S, Karimi A, Barzegary A, Mojdeganlou H, Vahedi F, Mirghaderi SP, et al. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. 2022;27(1):195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9547631</ArticleId><ArticleId IdType="pubmed">36209202</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A-rY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. New England Journal of Medicine. 2021;385(21):2010–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Shreyas Madhav A, Rajaraman R, Harini S, Kiliroor CC. Application of artificial intelligence to enhance collection of E-waste: A potential solution for household WEEE collection and segregation in India. Waste Management &amp; Research. 2022;40(7):1047–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109239</ArticleId><ArticleId IdType="pubmed">34726090</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal transduction and targeted therapy. 2020;5(1):237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551521</ArticleId><ArticleId IdType="pubmed">33051445</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines. 2021;9(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148145</ArticleId><ArticleId IdType="pubmed">34066475</ArticleId></ArticleIdList></Reference><Reference><Citation>Larijani MS, Ashrafian F, Amiri FB, Banifazl M, Bavand A, Karami A, et al. Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran. Microbial pathogenesis. 2022;169:105618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9176176</ArticleId><ArticleId IdType="pubmed">35690233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Frontiers in immunology. 2021;12:4149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542872</ArticleId><ArticleId IdType="pubmed">34707602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehraeen E, Oliaei S, SeyedAlinaghi S, Karimi A, Mirzapour P, Afsahi AM, et al. COVID-19 in Pediatrics: A Systematic Review of Current Knowledge and Practice. Infectious disorders drug targets. 2022;22(5):47–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">34587889</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836858</ArticleId><ArticleId IdType="pubmed">32702299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>BRISTOL Uo. ROBIS.  University of BRISTOL. 2023.  [Available from:  https://www.bristol.ac.uk/population-health-sciences/projects/robis/</Citation></Reference><Reference><Citation>Bhurwal A, Mutneja H, Bansal V, Goel A, Arora S, Attar B, et al. Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression. Alimentary Pharmacology &amp; Therapeutics. 2022;55(10):1244–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111455</ArticleId><ArticleId IdType="pubmed">35355306</ArticleId></ArticleIdList></Reference><Reference><Citation>Teh JS, Coussement J, Neoh ZC, Spelman T, Lazarakis S, Slavin MA, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances. 2022;6(7):2014–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639290</ArticleId><ArticleId IdType="pubmed">34852173</ArticleId></ArticleIdList></Reference><Reference><Citation>Shear S, Shams K, Weisberg J, Hamidi N, Scott S. COVID-19 vaccination safety profiles in patients with solid tumour cancers: a systematic review. Clinical Oncology. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014476</ArticleId><ArticleId IdType="pubmed">37019693</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SYS, Yee AM, Sim JJL, Lim CC. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology. 2023;62(5):1757–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9620290</ArticleId><ArticleId IdType="pubmed">36271852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K-T, Hsu B-C, Chen D-Y. Immunogenicity, effectiveness, and safety of COVID-19 vaccines in rheumatic patients: an updated systematic review and meta-analysis. Biomedicines. 2022;10(4):834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9030402</ArticleId><ArticleId IdType="pubmed">35453585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirasuthat S, Ratanapokasatit Y, Thadanipon K, Chanprapaph K. Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. 2024:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11094464</ArticleId><ArticleId IdType="pubmed">38698654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning F, Cao X-q, Wang Q-q, Li Z-y, Ruan Z, Chang T. Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis. Heliyon. 2024;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10796982</ArticleId><ArticleId IdType="pubmed">38261862</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Xia Y, Ye H, Sun X, Shi B, Wu J. Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis. Biomedical Reports. 2024;20(5):1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10999903</ArticleId><ArticleId IdType="pubmed">38590946</ArticleId></ArticleIdList></Reference><Reference><Citation>Efros O, Anteby R, Halfon M, Meisel E, Klang E, Soffer S. Efficacy and safety of third dose of the COVID-19 vaccine among solid organ transplant recipients: a systemic review and meta-analysis. Vaccines. 2022;10(1):95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778934</ArticleId><ArticleId IdType="pubmed">35062756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin M, Suelzer E, Ulschmid C, Thapa B, Szabo A, Abid MB. Efficacy of sars-cov-2 vaccine doses in allogeneic hemopoietic stem cell recipients: A systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention: APJCP. 2024;25(2):393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11077108</ArticleId><ArticleId IdType="pubmed">38415523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. Vaccines. 2021;9(10):1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8539812</ArticleId><ArticleId IdType="pubmed">34696210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, et al. Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis. J Clin Virol. 2022;153:105196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162782</ArticleId><ArticleId IdType="pubmed">35716417</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XH, Bao WJ, Zhang H, Fu SK, Jin HM. The Efficacy of SARS-CoV-2 Vaccination in the Elderly: A Systemic Review and Meta-analysis. Journal of General Internal Medicine. 2023;1:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10237071</ArticleId><ArticleId IdType="pubmed">37266884</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-García S, del Campo-Albendea L, Sambamoorthi D, Sheikh J, Lau K, Osei-Lah N, et al. Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis. BMJ Global Health. 2024;9(4):e014247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11002410</ArticleId><ArticleId IdType="pubmed">38580375</ArticleId></ArticleIdList></Reference><Reference><Citation>Januszek SM, Faryniak-Zuzak A, Barnaś E, Łoziński T, Góra T, Siwiec N, et al. The approach of pregnant women to vaccination based on a COVID-19 systematic review. Medicina. 2021;57(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8468958</ArticleId><ArticleId IdType="pubmed">34577900</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal S, Tackett RL, Stone RH, Young HN. COVID-19 vaccination among pregnant people in the United States: a systematic review. American journal of obstetrics &amp; gynecology MFM. 2022;4(4):100616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908633</ArticleId><ArticleId IdType="pubmed">35283351</ArticleId></ArticleIdList></Reference><Reference><Citation>Santimano AJ, Al-Zoubi RM, Al-Qudimat AR, Al Darwish MB, Ojha LK, Rejeb MA, et al. Efficacy and Clinical Outcomes of mRNA COVID-19 Vaccine in Pregnancy: A Systematic Review and Meta-Analysis. Intervirology. 2024;67(1):40–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11006275</ArticleId><ArticleId IdType="pubmed">38432215</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamb BMMAR, Chana KW, Chi IFNHS, Chana WTTM, Yapa DY-H. Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. mortality. 2024;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11095616</ArticleId><ArticleId IdType="pubmed">38751793</ArticleId></ArticleIdList></Reference><Reference><Citation>Glhoom S, Fergany A, El-Araby D, Abdelkhalek AA, Gomaa A, Zayed EO, et al. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis. European journal of medical research. 2024;29(1):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10768288</ArticleId><ArticleId IdType="pubmed">38183123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu C, Lin N, Zhu J, Ye Q. Association between Overweight/Obesity and the Safety and Efficacy of COVID-19 Vaccination: A Systematic Review. Vaccines (Basel) 2023;11(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10223724</ArticleId><ArticleId IdType="pubmed">37243100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval C, Guerrero D, Muñoz J, Godoy K, Souza-Mello V, Farías J. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: A systematic review. Expert Review of Vaccines. 2023;22(1):35–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">36484136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O, Mehraeen E, Karimi A, Tantuoyir MM, Afzalian A, Nazarian N, et al. Safety and adverse events related to inactivated COVID-19 vaccines and Novavax; a systematic review. Archives of Academic Emergency Medicine. 2022;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9397598</ArticleId><ArticleId IdType="pubmed">36033990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M-q, Weng Z-Y, Li R, Song G. Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: A systematic review and meta-analysis. Medicine. 2024;103(7):e35201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10869057</ArticleId><ArticleId IdType="pubmed">38363919</ArticleId></ArticleIdList></Reference><Reference><Citation>Primieri C, Bietta C, Giacchetta I, Chiavarini M, De Waure C. Determinants of COVID-19 vaccination acceptance or hesitancy in Italy: an overview of the current evidence. Annali dell'Istituto Superiore di Sanita. 2023;59(1):10–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">36974700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kacimi SEO, Klouche-Djedid SN, Riffi O, Belaouni HA, Yasmin F, Essar MY, et al. Determinants of COVID-19 Vaccine Engagement in Algeria: A Population-Based Study With Systematic Review of Studies From Arab Countries of the MENA Region. Frontiers in Public Health. 2022;10:843449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9196869</ArticleId><ArticleId IdType="pubmed">35712268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi YB, Thakkar S, Shah-Khan SM, Hutson W, Sarwari A, Singh S. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Gastroenterology. 2021;161(4):1336–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205252</ArticleId><ArticleId IdType="pubmed">34144044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, et al. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis. 2022;28(10):1497–505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822409</ArticleId><ArticleId IdType="pubmed">34871388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Tov A, Banon T, Chodick G, Kariv R, Assa A, Gazit S. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign. Gastroenterology. 2021;161(5):1715–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252826</ArticleId><ArticleId IdType="pubmed">34224740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelman MD, Weaver KN, Zhang X, Dai X, Watkins R, Adler J, et al. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2022;117(3):462–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35029167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Solera JT, Al-Alahmadi G, Marinelli T, Cardinal H, Poirier C, et al. Severity of COVID-19 among solid organ transplant recipients in Canada, 2020-2021: a prospective, multicentre cohort study. Cmaj. 2022;194(33):E1155–e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9435532</ArticleId><ArticleId IdType="pubmed">36302101</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcells ME, Le Corre N, Durán J, Ceballos ME, Vizcaya C, Mondaca S, et al. Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile. Clin Infect Dis. 2022;75(1):e594–e602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903589</ArticleId><ArticleId IdType="pubmed">35255140</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor KL, Kim SJ, Smith G, McArthur E, Kwong JC, Dixon SN, et al. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. Am J Transplant. 2022;22(9):2228–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347443</ArticleId><ArticleId IdType="pubmed">35578576</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B 1 617 2 (Delta) Variant. N Engl J Med. 2021;385(7):585–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425710</ArticleId><ArticleId IdType="pubmed">34396940</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177433</ArticleId><ArticleId IdType="pubmed">34109307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. Int Immunopharmacol. 2022;109:108906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148928</ArticleId><ArticleId IdType="pubmed">35671640</ArticleId></ArticleIdList></Reference><Reference><Citation>Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021;384(7):643–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787218</ArticleId><ArticleId IdType="pubmed">33378605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwak E, Kim T, Shin JY, Choi NK, Han S, Lee JY, et al. Effectiveness and Safety of COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National Population Study. J Korean Med Sci. 2023;38(41):e314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10593595</ArticleId><ArticleId IdType="pubmed">37873626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Shan Z, Gu Y, Huang Y. Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy. Int J Infect Dis. 2023;130:196–202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014124</ArticleId><ArticleId IdType="pubmed">36924838</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386(1):35–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561304</ArticleId><ArticleId IdType="pubmed">33069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(12):1645–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries. Vaccines (Basel) 2021;9:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8157062</ArticleId><ArticleId IdType="pubmed">34067682</ArticleId></ArticleIdList></Reference><Reference><Citation>Azanaw J, Endalew M, Zenbaba D, Abera E, Chattu VK. COVID-19 vaccine acceptance and associated factors in 13 African countries: A systematic review and meta-analysis. Front Public Health. 2022;10:1001423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9903367</ArticleId><ArticleId IdType="pubmed">36761336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y-J, Chan K-H, Hung IF-N. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines. 2021;9(9):989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473448</ArticleId><ArticleId IdType="pubmed">34579226</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, Oyama T, Fujimoto K, Shimizu T, Ozawa M, Amar JS, et al. Trash detection algorithm suitable for mobile robots using improved yolo. Journal of Advanced Computational Intelligence and Intelligent Informatics. 2023;27(4):622–31.</Citation></Reference><Reference><Citation>Rinaldi I, Pratama S, Wiyono L, Tandaju JR, Wardhana IL, Winston K. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis. Frontiers in Oncology. 2022;12:951215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393790</ArticleId><ArticleId IdType="pubmed">36003763</ArticleId></ArticleIdList></Reference><Reference><Citation>Barshan AD, Matsumoto-Takahashi ELA. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis. JMA journal. 2024;7(2):153–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11074501</ArticleId><ArticleId IdType="pubmed">38721084</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S-H, Yu S-Y, Kim J, Choi M, Choi YY, Choi JH, et al. Efficacy and Safety of COVID-19 Vaccines in Adolescents: Systematic Review of Randomized Controlled Studies and Observational Studies. Pediatric Infection &amp; Vaccine. 2024;31(1):12–24.</Citation></Reference><Reference><Citation>Song G, Li R, Cheng Mq. Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis. Journal of Medical Virology. 2024;96(4):e29625.</Citation><ArticleIdList><ArticleId IdType="pubmed">38650361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>